SOTIO is a biotechnology company developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit. SOTIO is owned by the PPF Group, one of the largest investment groups in Central and Eastern Europe.

The most advanced project is proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products.

SOTIO aims to become a mid-sized specialty pharma company that develops and commercializes innovative cancer therapeutics. We are building a diversified pipeline through internal development as well as strategic partnering. Our current licensing focus are innovative oncology therapies in advanced clinical stage.

Join Our Team

SOTIO is a biotechnology company that applies unique and novel procedures to develop new medicines. The company is looking for talented, motivated, dynamic employees to join its international team ...

Business Development Capabilities

PPF has a vision to build a diversified biotech portfolio of innovative therapies for the treatment of cancer. SOTIO aims to become a diverse oncology specialty pharma company. We seek to add ...

NEWS April 10, 2018

SOTIO to Present Translational Data of the IL-15 Superagonist SO-C101 at 2018 AACR Annual Meeting

SOTIO, a biotechnology company owned by the PPF Group, announces today presentation of a poster on SO-C101 at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2018. The ...

Clinical Trials

Prostate Cancer

DCVAC/PCa Clinical Trials - besides global Phase III VIABLE study we have initiated five Phase II clinical trials for patients with prostate cancer at various stages of the disease. Around 1500 patients at different stages of the disease participated in these trials. We are also preparing clinical trials evaluating combination of DCVAC/PCa and other promising treatment methods.

Ovarian Cancer

Phase II Clinical Trials of DCVAC/OvCa - four Phase II clinical trials have been launched to assess the effect of addition of DCVAC platform (DCVAC/OvCa) to standard of care chemotherapy in patients with ovarian cancer at various stages of the disease. SOV01 and SOV06 clinical trials are currently enrolling patients with epithelial ovarian cancer.

Lung Cancer

Phase I/II Clinical Trial DCVAC/LuCa - SLU01 study was launched to assess the use of DCVAC platform (DCVAC/LuCa) combined with standard treatments in patients with advanced lung cancer. This clinical trial recruited patients at medical centers in the Czech Republic and Slovakia and is currently in the phase of final evaluation.

Learn more about Active Cellular Immunotherapy focusing on the treatment of cancer diseases.

Contacts

Boston
Boston
SOTIO LLC
180 Canal St,
Suite 300
Boston, MA 02114
USA
CONTACT
Prague
Prague
SOTIO a.s.
Jankovcova 1518/2
170 00 Prague 7
Czech Republic
CONTACT
Moscow
Moscow
SOTIO LLC
Pravdy Street, 8,
bld. 1 (8th Floor)
Moscow 125040
Russia
CONTACT
Beijing
Beijing
SOTIO Medical Research (Beijing) Co., Ltd.
Beijing Economic - Technological Dev. Area
99 Kechuang 14, 30-B
Beijing 100176
China
CONTACT
We use cookies to give you the best possible experience on our website. More information